Sun Pharma inks pact with Bayer to sell drug for chronic kidney disease
Under the terms of the agreement, Bayer has granted non-exclusive rights to Sun Pharma to market and distribute a second Finerenone product under the brand name Lyvelsa. Finerenone was first launched by Bayer under the brand name Kerendia in 2022.
"This partnership underscores our commitment to make innovative medicines available to patients in India," Sun Pharma India Business CEO Kirti Ganorkar said in a statement. Image Gathered from Reuters.